If the SOUL study corroborates the findings of this model, it may not only form the basis for the calculation of power but also define the duration of such studies, reducing costs and easing the process of designing cardiovascular outcome trials (CVOTs)
APs induce signficiant weight gain in individuals with intellectual and/or developmental disabilities, an already vulnerable population with intrinsic risk of metabolic dysregulation
Benign neuroendocrine tumors, such as insulinomas, gastrinomas, pheochromocytomas, and certain bronchial or cerebral neuroendocrine neoplasms, often exhibit high and uniform GLP-1R expression, making them ideal targets for GLP-1R-targeted therapy and diagnosis [508, 509]
Typically, IR formulations start to work within 30 to 60 minutes after ingestion, providing a rapid onset of effects